Navigation Links
Mount Sinai researchers awarded 'Provocative Questions' grant from National Cancer Institute
Date:9/20/2012

Two Mount Sinai School of Medicine researchers are among a select group of scientists from around the world who have been recognized by the National Cancer Institute (NCI) for their quest to answer the most pressing questions about cancer. Stuart Aaronson, MD, Professor and Chair of Oncological Sciences and Ross Cagan, PhD, Professor of Oncological Sciences at Mount Sinai, have received the NCI's new "Provocative Questions" grant, which was established to explore the important yet less obvious questions about cancer that may have been neglected in this era of significant discovery.

Provocative Question: Why do many cancer cells die when suddenly deprived of a protein encoded by an oncogene?

The grant will support Dr. Aaronson's research on signaling pathways responsible for a little-understood phenomenon called oncogene addiction. Oncogenes are mutant genes that scientists believe are key to tumor survival and progression. Disruption of the signaling pathway in these oncogenes has been shown to halt tumor growth or lead to tumor cell death. Dr. Aaronson's lab is exploring the signaling activity of one such pathway called Wnt, which plays a key role in regulating self-renewal of a variety of embryonic and adult stem cells and is a starting point for tumor development.

Dr. Aaronson's lab has found that inhibition of activated Wnt signaling can block growth and complement the effects of chemotherapy and radiation, leading to tumor cell death. The goals of this grant are to investigate the signaling pathways responsible for Wnt oncogene addiction, and discover its molecular basis.

"While increasing efforts are being made to develop effective inhibitors of Wnt signaling in tumors, to date, few, if any, have entered into clinical development," said Dr. Aaronson. "Our NCI grant will support our research to identify and characterize specific and potent Wnt-targeted drugs that can disrupt this oncogene addiction in tumor cell
'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Studies shed light on how to reduce the amount of toxins in plant-derived foods
2. Increase in metal concentrations in Rocky Mountain watershed tied to warming temperatures
3. IdentiSys acquires the Identification, Security and Presentation Divisions of Mountainland Business Systems, a Utah based reseller
4. Mount Sinai researchers solve mystery surrounding the death of two sisters nearly 50 years ago
5. NCEAS DataONE streamlines search and analysis of massive amounts of ecological data
6. Nitrogen pollution changing Rocky Mountain National Park vegetation, says CU-Boulder-led study
7. Medbox Developing a Patent Pending Wall-Mounted Biometric Kiosk for Storage of Sensitive Medicine Samples and Supplies for Doctors Offices.
8. European mountain plant population shows delayed response to climate change
9. Global warming has driven Europes mountain plants to migrate 2.7 meters upwards in 7 years
10. Accelerating climate change exerts strong pressure on Europes mountain flora
11. CU research shows warming climate threatens ecology at mountain research site west of Boulder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2014)... – University of Utah engineers developed the first room-temperature ... produce electricity without needing to ignite the fuel. These ... electronics, off-grid power and sensors. , A study of ... Chemical Society journal ACS Catalysis . , Fuel ... between a fuel and an oxygen-rich source such as ...
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® , ... life sciences company focused on commercialization of its ... for the treatment of neurological and neuropsychiatric disorders, ... Property has issued a Notice of Allowance for ... is co-owned by NeuroSigma and the Regents of ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Although the soluble factor TGF-beta has been shown to suppress ... breast cancer, high levels of TGF-beta during the later stages ... study using human breast cancer samples and mice, which appears ... January print issue of the Journal of Clinical Investigation, indicates ...
... successfully tested two candidate vaccines that may eventually be ... Their findings are published in the December 15 issue ... , Barney S. Graham, MD, PhD, and colleagues from ... in Maryland, the Fred Hutchinson Cancer Research Center in ...
... the University of Rochester may have answered one of ... neurons, which are responsible for our crystal-clear thoughts, seem ... November issue of Nature Neuroscience, the Rochester study shows ... signals to represent the ambiguities of the real world--and ...
Cached Biology News:Progress made in HIV vaccine development 2Mysterious 'neural noise' actually primes brain for peak performance 2Mysterious 'neural noise' actually primes brain for peak performance 3
(Date:11/26/2014)... November 25, 2014 Silicon Valley Electronic ... with RPM Alliance , provider of clinical research ... With the latest addition to its CRO Partnership Program, ... EDC system to India. , “We have found ... and customizable EDC platform which is both user friendly ...
(Date:11/26/2014)... SoundConnect , an award winning ... announce that Darren Suders has joined the team as ... drive the partner program through innovative offerings, ... , Darren brings more than 10-years of channel telecommunication ... channel operations, from policy development, to partner education and ...
(Date:11/26/2014)... -- Theravalues Corporation annuncia con orgoglio il lancio di ... Hi Europe 2014 (dal 2 al 4 dicembre, ... curcumina con la maggiore biodisponibilità di sempre, con una ... dalle norme europee. La curcumina è un ... Curcuma longa ) che è stata associata con attività ...
(Date:11/24/2014)... , Nov. 24, 2014 VolitionRx Limited ... tests for cancer and other conditions, today announced that data ... the Science for Business BioWin Day 2014, being held November ... data come from VolitionRx,s lung cancer pilot study, the samples ... Centre Hospitalier Universitaire (CHU) de Liege in Belgium ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... Calif., Jan. 22 Abaxis, Inc.,(Nasdaq: ABAX ), ... scheduled a conference call to discuss its,financial results for ... 2007. The call will be at 4:15 p.m. ET, ... 356-5706 or (706) 643-0580 to access the,conference call, or ...
... 8:30 a.m. EST at ... http://www.isispharm.com , ... ) announced today that Abbott is,investing up to $40 million in ... further develop the Ibis T5000(TM),Biosensor System, which offers a unique solution ...
... Marker Precision and ... Simultaneous Diagnostic Monitoring MUKILTEO, Wash. ... CBMX ) and Clarient, Inc. (Nasdaq: CLRT ),today ... a novel genomics-based cancer test called HemeScan(TM), a,comprehensive test related ...
Cached Biology Technology:Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31, 2008 2Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 2Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 3Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity 4CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 2CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 3CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 4CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 5CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 6
Mouse BLC/BCA 1 - 10kDa...
Bag-1 (K-20)...
... PGE2-d4 contains 4 deuterium atoms at ... It is intended for use as an ... E2 (PGE2) by GC- or LC-mass spectrometry. ... products of arachidonic acid and one of ...
Deletions, insertions or substitutions. Mutations in plasmids of size up to 15 kb. Single or multiple mutations...
Biology Products: